4882.T

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Drug Manufacturers - General

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$120M	-90.9%	$-62.50	$-62.50–$-62.50	—	1
2028	$887M	+639.2%	$-13.30	$-13.30–$-13.30	—	1
2029	$150M	-83.1%	$0.00	$0.00–$0.00	—	0
2030	$161M	+7.3%	$0.00	$0.00–$0.00	—	0

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
4882.TPerseus Proteomics Inc.	$171.00	+0.59%	$3.2B	—
4570.TImmuno-Biological Laboratories Co., Ltd.	$1162.00	+0.26%	$10.8B	—
4572.TCarna Biosciences, Inc.	$432.00	+0.70%	$8.3B	—
4576.TD. Western Therapeutics Institute, Inc.	$69.00	-20.69%	$4.0B	—
4591.TRibomic Inc.	$79.00	-2.47%	$4.4B	—
4596.TKubota Pharmaceutical Holdings Co., Ltd.	$67.00	+1.52%

Source: Financial Modeling Prep · peers by sector/industry

Perseus Proteomics Inc.

Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.

www.ppmx.com

Employees: 35
IPO / List date: Jun 22, 2021
HQ: JP

Held by traders on TradeandTell

No one on the platform currently holds 4882.T.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 4882.T as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 4882.T yet.